VRNA vs. FINV
Compare and contrast key facts about Verona Pharma plc (VRNA) and FinVolution Group (FINV).
Performance
VRNA vs. FINV - Performance Comparison
Loading graphics...
VRNA vs. FINV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
VRNA Verona Pharma plc | 0.00% | 130.21% | 133.60% | -23.92% | 288.84% | -4.00% | 21.74% | -40.41% | -18.71% | -4.88% |
FINV FinVolution Group | -8.41% | -20.07% | 45.47% | 4.39% | 6.39% | 89.23% | 8.51% | -22.85% | -49.37% | -45.64% |
Fundamentals
VRNA:
$9.72B
FINV:
$1.27B
VRNA:
-$0.69
FINV:
$9.51
VRNA:
57.97
FINV:
0.09
VRNA:
34.92
FINV:
0.08
VRNA:
$167.65M
FINV:
$13.53B
VRNA:
$159.52M
FINV:
$10.64B
VRNA:
-$40.86M
FINV:
$3.00B
Returns By Period
VRNA
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
FINV
- 1D
- 1.70%
- 1M
- -14.77%
- YTD
- -8.41%
- 6M
- -35.01%
- 1Y
- -48.38%
- 3Y*
- 9.76%
- 5Y*
- -2.92%
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
VRNA vs. FINV — Risk / Return Rank
VRNA
FINV
VRNA vs. FINV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and FinVolution Group (FINV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Loading graphics...
Sharpe Ratios by Period
| VRNA | FINV | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | — | -1.01 | — |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.06 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | — | -0.11 | — |
Correlation
The correlation between VRNA and FINV is 0.09, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
VRNA vs. FINV - Dividend Comparison
VRNA has not paid dividends to shareholders, while FINV's dividend yield for the trailing twelve months is around 5.78%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
VRNA Verona Pharma plc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
FINV FinVolution Group | 5.78% | 5.30% | 3.49% | 4.39% | 4.13% | 3.45% | 4.49% | 7.17% |
Drawdowns
VRNA vs. FINV - Drawdown Comparison
Loading graphics...
Drawdown Indicators
| VRNA | FINV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | — | -89.64% | — |
Max Drawdown (1Y)Largest decline over 1 year | — | -56.42% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -70.54% | — |
Current DrawdownCurrent decline from peak | — | -54.81% | — |
Average DrawdownAverage peak-to-trough decline | — | -53.77% | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 35.66% | — |
Volatility
VRNA vs. FINV - Volatility Comparison
Loading graphics...
Volatility by Period
| VRNA | FINV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | — | 20.26% | — |
Volatility (6M)Calculated over the trailing 6-month period | — | 37.63% | — |
Volatility (1Y)Calculated over the trailing 1-year period | — | 48.08% | — |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | — | 50.51% | — |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | — | 72.22% | — |
Financials
VRNA vs. FINV - Financials Comparison
This section allows you to compare key financial metrics between Verona Pharma plc and FinVolution Group. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
VRNA vs. FINV - Profitability Comparison
VRNA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.
FINV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, FinVolution Group reported a gross profit of 2.15B and revenue of 2.98B. Therefore, the gross margin over that period was 72.0%.
VRNA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.
FINV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, FinVolution Group reported an operating income of 475.99M and revenue of 2.98B, resulting in an operating margin of 16.0%.
VRNA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.
FINV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, FinVolution Group reported a net income of 418.85M and revenue of 2.98B, resulting in a net margin of 14.1%.